Letters Second generation antidepressants

Author’s reply to Straton

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2284 (Published 27 March 2012) Cite this as: BMJ 2012;344:e2284
  1. Gerald Gartlehner, clinical epidemiologist1
  1. 1RTI-UNC Evidence-based Practice Center (USA), Austrian Cochrane Branch, 3500 Krems, Austria
  1. gerald.gartlehner{at}donau-uni.ac.at

Straton raises an interesting point, but his conclusion loses sight of an important factor in any statistical analysis—uncertainty.1 2 All fluvoxamine comparisons (in our 2008 and 2011 reviews) are encompassed by substantial uncertainty, as shown by …

Sign in

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe